CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Adult Tussin

Guaifenesin· ingredient guaifenesin· GUAIFENESIN 100 mg/5mL; GUAIFENESIN 200 mg/10mL; GUAIFENESIN 300 mg/15mL; GUAIFENESIN 400 mg/20mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.01815
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per ML — the trend nobody else shows. 7 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other guaifenesin products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.

ProductNADAC / MLvs this
Leader Adult Tussin Mucus and Chest Congestion 541$0.02236+$0.00420
Guaifenesin 200mg$0.03140+$0.01320
Always Save Chest Congestion Relief GUAF$0.06723+$0.04910
Always Save Mucus Relief PE$0.08718+$0.06900
12 Hour Mucus Relief$0.29751+$0.27940
equate mucus d$0.36492+$0.34680
EQUATE MUCUS D$0.41980+$0.40170
basic care mucus er max$0.44813+$0.43000

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.